文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

一种带锚定凸缘的新型部分覆膜自膨式金属支架用于超声内镜引导下肝胃吻合术的初步可行性研究(附视频)

Preliminary feasibility study of a new partially covered self-expandable metal stent with an anchoring flange for EUS-guided hepaticogastrostomy (with videos).
PubMed 文献 · Gastrointest Endosc · 2023-07-18

本研究在24例不可切除恶性胆道梗阻患者中评估一种带锚定凸缘的新型部分覆膜自膨式金属支架用于超声内镜引导下肝胃吻合术(EUS-HPG)的可行性。EUS-HPG技术成功率和临床成功率分别为100%(24/24)和91.7%(22/24),不良事件发生率为8.3%(2/24,胆管炎),复发性胆道梗阻发生率为29.2%(7/24)。作者认为该新型支架可能预防支架相关不良事件(包括支架移位),并允许经肝胃吻合途径进行先进内镜干预。

要点

  • EUS-HPG技术成功率为100%(24/24),临床成功率为91.7%(22/24)。
  • EUS-HPG后不良事件发生率为8.3%(2/24),均为胆管炎。
  • 复发性胆道梗阻发生率为29.2%(7/24),中位累积发生时间为6.7个月。

核心结论

  • 使用新型部分覆膜自膨式金属支架行EUS-HPG可在经内镜逆行胰胆管造影术失败后缓解恶性胆道梗阻。
  • 本研究所评估的新型支架可能预防支架相关不良事件(包括支架移位),并允许经肝胃吻合途径进行先进内镜干预。

研究设计与样本

  • 连续纳入因不可切除恶性胆道梗阻行EUS-HPG的患者,评估一种带锚定凸缘的新型部分覆膜自膨式金属支架的可行性。
  • 该支架近端为长1.5 cm的射线不可透部分覆膜段,远端为直径20 mm的锚定凸缘。
  • 主要结局为EUS-HPG的技术成功和临床成功,次要结局为不良事件、复发性胆道梗阻、复发性胆道梗阻的再干预及支架在位时经口胆管镜的技术可行性。

主要发现

  • 共24例不可切除恶性胆道梗阻患者行EUS-HPG。
  • EUS-HPG技术成功率为100%(24/24),临床成功率为91.7%(22/24)。
  • EUS-HPG后8.3%的患者(2/24)发生不良事件,均为胆管炎。
  • 29.2%的患者(7/24)发生复发性胆道梗阻,中位累积发生时间为6.7个月;原因包括污泥形成(n=4)、未覆膜部分增生(n=2)和非闭塞性胆管炎(n=1)。
  • 复发性胆道梗阻的再干预成功率为100%(7/7);在支架直径为10 mm的8例患者中,有7例经口胆管镜通过在位支架技术可行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: EUS-guided hepaticogastrostomy (EUS-HPG) has a risk of serious procedural adverse events (AEs), but few dedicated devices for EUS-HPG are available. We evaluated the feasibility of a new partially covered self-expandable metal stent (PCSEMS) with an anchoring flange for EUS-HPG. METHODS: The feasibility of a stent featuring a proximal radiopaque uncovered portion 1.5 cm in length and a distal anchoring flange 20 mm in diameter was evaluated in consecutive patients undergoing EUS-HPG for unresectable malignant biliary obstruction. Primary outcomes were the technical and clinical success of EUS-HPG, and secondary outcomes were AEs, recurrent biliary obstruction (RBO), reintervention for RBO, and the technical feasibility of peroral cholangioscopy (POC) through the stent in situ. RESULTS: EUS-HPG was performed in 24 patients with unresectable malignant biliary obstruction. The technical and clinical success rates of EUS-HPG were 100% (24/24) and 91.7% (22/24), respectively. AEs developed after EUS-HPG in 8.3% of patients (2/24, cholangitis). RBO developed in 29.2% of patients (7/24), with a median cumulative time to RBO of 6.7 months. The causes of RBO were sludge formation (n = 4), hyperplasia at an uncovered portion (n = 2), and nonocclusive cholangitis (n = 1). Reintervention for RBO had a 100% success rate (7/7), and POC through the stent in situ was technically feasible in 7 of 8 patients with a stent diameter of 10 mm. CONCLUSIONS: EUS-HPG with a new PCSEMS can alleviate malignant biliary obstruction after failed ERCP. The novel stent evaluated in this study may prevent stent-related AEs, including stent migration, and allow advanced endoscopic interventions through the HPG route.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Shin IS, Moon JH, Lee YN, et al. Preliminary feasibility study of a new partially covered self-expandable metal stent with an anchoring flange for EUS-guided hepaticogastrostomy (with videos). Gastrointest Endosc. 2023. PMID: 37473968. doi:10.1016/j.gie.2023.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。